AVC-001 / AvenCell Therap, BMS - LARVOL DELTA

Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (clinicaltrials.gov) - P1 | N=23 | Terminated | Sponsor: AvenCell Europe GmbH | Recruiting ➔ Terminated | Trial primary completion date: Dec 2022 ➔ Jun 2023; business decision by sponsor

Trial primary completion date • Trial termination • Genito-urinary Cancer • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • CTCs • PSCA

Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: AvenCell Europe GmbH | Trial completion date: Dec 2022 ➔ Jun 2023 | Trial primary completion date: Jun 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • CTCs • PSCA

Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: GEMoaB Monoclonals GmbH; Trial completion date: Feb 2021 ➔ Dec 2022; Trial primary completion date: Dec 2020 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatology • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: GEMoaB Monoclonals GmbH

Clinical • New P1 trial

Newly added product (PRNewswire) - P1, Breast Cancer, NSCLC, GU Cancer, Pancreatic Cancer

Pipeline update

GEMoaB announces first patient dosed with the affinity-tailored T-cell-adaptor GEM3PSCA in a phase I study in PSCA-positive late-stage solid tumors (PRNewswire) - "GEMoaB GmbH....announced the dosing of the first patient in a Phase I open-label, dose escalation study of GEM3PSCA, an Affinity-Tailored Adapter for T-Cells (ATAC). The bispecific antibody binds to the CD3-Receptor on T-cells and prostate stem cell antigen (PSCA), differentially and broadly expressed in a variety of late stage solid tumors, such as castrate-resistant prostate cancer, pancreatic and breast cancer, bladder and renal cancer as well as non-small cell lung cancer."

Trial status